MX2013005050A - Derivados de indol. - Google Patents
Derivados de indol.Info
- Publication number
- MX2013005050A MX2013005050A MX2013005050A MX2013005050A MX2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A MX 2013005050 A MX2013005050 A MX 2013005050A
- Authority
- MX
- Mexico
- Prior art keywords
- indole derivatives
- bradykinin
- racemates
- painful
- therapy
- Prior art date
Links
- 229940054051 antipsychotic indole derivative Drugs 0.000 title abstract 2
- 150000002475 indoles Chemical class 0.000 title abstract 2
- 101800004538 Bradykinin Proteins 0.000 abstract 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 1
- 102100035792 Kininogen-1 Human genes 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 239000008196 pharmacological composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se relaciona con los derivados de indol de la fórmula (I), donde R1-R6 y X se definen en las reivindicaciones, con los antípodos ópticos o los racematos y/o las sales de los mismos que son antagonistas selectivos de la bradiquinina B1, con el proceso para producir estos compuestos, con las composiciones farmacológicas que los contienen y con su uso en la terapia o en la prevención de las condiciones dolorosas e inflamatorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000598A HUP1000598A2 (en) | 2010-11-05 | 2010-11-05 | Indole derivatives |
| PCT/HU2011/000104 WO2012059776A1 (en) | 2010-11-05 | 2011-11-04 | Indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013005050A true MX2013005050A (es) | 2013-12-06 |
Family
ID=89990047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013005050A MX2013005050A (es) | 2010-11-05 | 2011-11-04 | Derivados de indol. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20130217702A1 (es) |
| EP (1) | EP2635567B1 (es) |
| JP (1) | JP2013542951A (es) |
| KR (1) | KR20130130733A (es) |
| CN (1) | CN103201276B (es) |
| AP (1) | AP2013006867A0 (es) |
| AU (1) | AU2011324958A1 (es) |
| BR (1) | BR112013011192A2 (es) |
| CA (1) | CA2812655A1 (es) |
| CU (1) | CU24136B1 (es) |
| EA (1) | EA022939B1 (es) |
| HU (2) | HUP1000598A2 (es) |
| IL (1) | IL225393A0 (es) |
| MX (1) | MX2013005050A (es) |
| NZ (1) | NZ610699A (es) |
| PH (1) | PH12013500588A1 (es) |
| SG (1) | SG189833A1 (es) |
| WO (1) | WO2012059776A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12023319B2 (en) | 2016-12-23 | 2024-07-02 | Bayer Pharma Aktiengesellschaft | Carboxylic acid aromatic amides |
| CA3047812A1 (en) | 2016-12-23 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Tetrazole containing compounds |
| JOP20190156B1 (ar) | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
| CN112573978B (zh) * | 2019-09-30 | 2022-05-13 | 北京大学 | 一种芳基卤化物的高效卤化合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ227841A (en) | 1988-02-12 | 1991-08-27 | Merck Sharp & Dohme | Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions |
| GB9716656D0 (en) | 1997-08-07 | 1997-10-15 | Zeneca Ltd | Chemical compounds |
| FR2822827B1 (fr) | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| WO2002099388A2 (en) | 2001-06-07 | 2002-12-12 | Merck & Co., Inc. | Benzodiazepine bradykinin antagonists |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| TWI259079B (en) * | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
| MXPA05002245A (es) * | 2002-08-29 | 2005-06-08 | Merck & Co Inc | Derivados de n-biarilmetil aminocicloalcancarboxamida. |
| US6908921B2 (en) | 2002-12-13 | 2005-06-21 | Merck & Co., Inc. | Quinoxalinone derivatives as bradykinin B1 antagonists |
| EP1643960A2 (en) | 2003-07-02 | 2006-04-12 | Merck & Co., Inc. | Arylsulfonamide derivatives |
| CA2534188A1 (en) * | 2003-08-07 | 2005-02-24 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| CN1832922A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 磺酰基取代的n－(联芳基甲基)氨基环丙烷甲酰胺类 |
| CN1926136A (zh) * | 2004-03-02 | 2007-03-07 | 默克公司 | 作为缓激肽拮抗剂的氨基环丙烷羧酰胺衍生物 |
| US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| SI1828167T1 (sl) | 2004-06-04 | 2014-12-31 | Debiopharm International Sa Forum "Apres-Demain" | Akrilamidni derivati kot anitibiotična sredstva |
| US20100286211A1 (en) | 2004-10-08 | 2010-11-11 | Biswajit Das | Oxazolidinone derivatives as antimicrobials |
| MX2008000886A (es) | 2005-07-21 | 2008-03-18 | Hoffmann La Roche | Derivados de indol-3-il-carbonil-piperidin-benzoimidazol como antagonistas del receptor v1a. |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| WO2007101007A2 (en) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Aryl sulfonyl heterocycles |
| DE102007034620A1 (de) | 2007-07-25 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue B1-Antagonisten |
| AR068509A1 (es) | 2007-09-19 | 2009-11-18 | Jerini Ag | Antagosnistas del receptor de bradiquinina b1 |
| AU2009235634B8 (en) | 2008-04-08 | 2013-05-23 | Grunenthal Gmbh | Substituted sulfonamide derivatives |
| US20090270394A1 (en) * | 2008-04-28 | 2009-10-29 | Galemmo Jr Robert | Cyclylamine derivatives as calcium channel blockers |
| CN102414177B (zh) * | 2009-02-26 | 2014-07-02 | 贝林格尔.英格海姆国际有限公司 | 作为缓激肽b1拮抗剂的化合物 |
-
2010
- 2010-11-05 HU HU1000598A patent/HUP1000598A2/hu unknown
-
2011
- 2011-11-04 WO PCT/HU2011/000104 patent/WO2012059776A1/en not_active Ceased
- 2011-11-04 EP EP11788570.7A patent/EP2635567B1/en active Active
- 2011-11-04 AP AP2013006867A patent/AP2013006867A0/xx unknown
- 2011-11-04 KR KR1020137014219A patent/KR20130130733A/ko not_active Withdrawn
- 2011-11-04 SG SG2013025226A patent/SG189833A1/en unknown
- 2011-11-04 EA EA201300541A patent/EA022939B1/ru not_active IP Right Cessation
- 2011-11-04 NZ NZ610699A patent/NZ610699A/en not_active IP Right Cessation
- 2011-11-04 AU AU2011324958A patent/AU2011324958A1/en not_active Abandoned
- 2011-11-04 CA CA2812655A patent/CA2812655A1/en not_active Abandoned
- 2011-11-04 PH PH1/2013/500588A patent/PH12013500588A1/en unknown
- 2011-11-04 CN CN201180053024.8A patent/CN103201276B/zh not_active Expired - Fee Related
- 2011-11-04 CU CU20130065A patent/CU24136B1/es unknown
- 2011-11-04 JP JP2013537214A patent/JP2013542951A/ja active Pending
- 2011-11-04 US US13/823,221 patent/US20130217702A1/en not_active Abandoned
- 2011-11-04 MX MX2013005050A patent/MX2013005050A/es active IP Right Grant
- 2011-11-04 HU HUE11788570A patent/HUE026652T2/en unknown
- 2011-11-04 BR BR112013011192A patent/BR112013011192A2/pt not_active IP Right Cessation
-
2013
- 2013-03-21 IL IL225393A patent/IL225393A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013011192A2 (pt) | 2016-08-02 |
| US20130217702A1 (en) | 2013-08-22 |
| HUE026652T2 (en) | 2016-07-28 |
| EA201300541A1 (ru) | 2013-08-30 |
| EA022939B1 (ru) | 2016-03-31 |
| SG189833A1 (en) | 2013-06-28 |
| NZ610699A (en) | 2015-08-28 |
| CN103201276A (zh) | 2013-07-10 |
| CU24136B1 (es) | 2015-11-27 |
| AP2013006867A0 (en) | 2013-05-31 |
| WO2012059776A1 (en) | 2012-05-10 |
| AU2011324958A1 (en) | 2013-06-06 |
| CN103201276B (zh) | 2015-02-25 |
| IL225393A0 (en) | 2013-06-27 |
| HUP1000598A2 (en) | 2012-09-28 |
| EP2635567B1 (en) | 2015-10-28 |
| CA2812655A1 (en) | 2012-05-10 |
| HU1000598D0 (en) | 2010-12-28 |
| JP2013542951A (ja) | 2013-11-28 |
| KR20130130733A (ko) | 2013-12-02 |
| CU20130065A7 (es) | 2013-07-31 |
| PH12013500588A1 (en) | 2015-11-06 |
| EP2635567A1 (en) | 2013-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY162535A (en) | Inhibitors of arginase and their therapeutic applications | |
| EA201590879A1 (ru) | Арилконденсированные и гетероарилконденсированные лактамы | |
| UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
| PH12013501175A1 (en) | 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors | |
| PH12013500329A1 (en) | New compounds | |
| MX2015000892A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| MX336381B (es) | Boronatos como inhibidores de arginasa. | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| PH12012501589A1 (en) | Macrocycles as factor xia inhibitors | |
| EA201490418A1 (ru) | Новые макроциклические соединения в качестве ингибиторов фактора xia | |
| MY196427A (en) | Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors | |
| MX2015000919A (es) | Dihidropiridona p1 como inhibidores del factor xia. | |
| TN2014000016A1 (en) | 4 - piperidinyl compounds for use as tankyrase inhibitors | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| MX2013004759A (es) | Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl). | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| MX2013012652A (es) | Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12. | |
| PH12013501800A1 (en) | Tricyclic gyrase inhibitors | |
| MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
| MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
| PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
| MX2013005819A (es) | Benzoxazepinas como inhibidores de 3-cinasa/objetivo mamífero de rapamicina (pi3k/mtor) metodos de uso y fabricacion. | |
| MX359399B (es) | Inhibidores de 17alfa-hidroxilasa/c17-20-liasa. | |
| PH12013500588A1 (en) | Indole derivatives | |
| MD20160111A2 (ro) | Derivaţi diheterociclici legaţi de cicloalchil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |